PMC:7283670 / 83195-83981 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T273","span":{"begin":77,"end":90},"obj":"Body_part"},{"id":"T274","span":{"begin":77,"end":88},"obj":"Body_part"},{"id":"T275","span":{"begin":98,"end":108},"obj":"Body_part"},{"id":"T276","span":{"begin":127,"end":134},"obj":"Body_part"},{"id":"T277","span":{"begin":354,"end":359},"obj":"Body_part"}],"attributes":[{"id":"A273","pred":"fma_id","subj":"T273","obj":"http://purl.org/sig/ont/fma/fma264829"},{"id":"A274","pred":"fma_id","subj":"T274","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A275","pred":"fma_id","subj":"T275","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A276","pred":"fma_id","subj":"T276","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A277","pred":"fma_id","subj":"T277","obj":"http://purl.org/sig/ont/fma/fma67498"}],"text":"Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T176","span":{"begin":354,"end":359},"obj":"Body_part"}],"attributes":[{"id":"A176","pred":"uberon_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T689","span":{"begin":77,"end":90},"obj":"http://purl.obolibrary.org/obo/PR_000001393"},{"id":"T690","span":{"begin":354,"end":359},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"}],"text":"Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T328","span":{"begin":127,"end":134},"obj":"Chemical"},{"id":"T329","span":{"begin":196,"end":202},"obj":"Chemical"},{"id":"T330","span":{"begin":231,"end":237},"obj":"Chemical"}],"attributes":[{"id":"A328","pred":"chebi_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A329","pred":"chebi_id","subj":"T329","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A330","pred":"chebi_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms"}

{"project":"LitCovid-sentences","denotations":[{"id":"T725","span":{"begin":25,"end":49},"obj":"Sentence"},{"id":"T726","span":{"begin":50,"end":76},"obj":"Sentence"},{"id":"T727","span":{"begin":77,"end":699},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1857","span":{"begin":77,"end":90},"obj":"Gene"},{"id":"1858","span":{"begin":116,"end":134},"obj":"Gene"},{"id":"1948","span":{"begin":447,"end":459},"obj":"Species"},{"id":"1949","span":{"begin":732,"end":739},"obj":"Species"}],"attributes":[{"id":"A1857","pred":"tao:has_database_id","subj":"1857","obj":"Gene:3569"},{"id":"A1858","pred":"tao:has_database_id","subj":"1858","obj":"Gene:1401"},{"id":"A1948","pred":"tao:has_database_id","subj":"1948","obj":"Tax:9606"},{"id":"A1949","pred":"tao:has_database_id","subj":"1949","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Primary (up to 1 month):\nOne‐month mortality rate\nSecondary (up to 1 month):\ninterleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms"}